Back to top
more

BioXcel Therapeutics (BTAI)

(Delayed Data from NSDQ)

$2.63 USD

2.63
260,295

+0.02 (0.77%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $2.61 -0.02 (-0.76%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

BioXcel Therapeutics, Inc. [BTAI]

Reports for Purchase

Showing records 61 - 80 ( 107 total )

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 61

03/19/2020

Company Report

Pages: 5

BXCL501 Pivotal Phase 3 Program Enrollment Update; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 62

03/19/2020

Company Report

Pages: 5

BXCL501 Pivotal Phase 3 Program Enrollment Update; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 63

03/17/2020

Company Report

Pages: 7

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 64

03/10/2020

Company Report

Pages: 5

2019 Financial Results; SERENITY and TRANQUILITY Advancing; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 65

02/28/2020

Company Report

Pages: 9

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 66

02/26/2020

Company Report

Pages: 10

Pipeline in a Single Product Story Materializing; Raising PT to $95

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 67

02/05/2020

Company Report

Pages: 5

RELEASE Trial Authorization Granted; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 68

01/10/2020

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 69

01/08/2020

Company Report

Pages: 5

BXCL501 Phase 1b/2 Trial Starts Enrollment; Reiterate Buy; Raising PT to $30

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 70

12/30/2019

Company Report

Pages: 5

SERENITY Pivotal Program Initiates Enrollment; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 71

12/12/2019

Company Report

Pages: 5

BXCL701 Clinical Assessment Expansion Into Multiple Solid Tumor Types; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 72

12/11/2019

Company Report

Pages: 5

SERENITY Pivotal Program Gets FDA Green Light; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 73

12/06/2019

Company Report

Pages: 6

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 74

11/21/2019

Company Report

Pages: 8

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 75

11/20/2019

Company Report

Pages: 5

Pivotal BXCL501 Program Starting Soon; 3Q19 Financials Reported; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 76

10/30/2019

Company Report

Pages: 19

Provider: Zacks Investment Research

Analyst: Research Department

Price: 24.95

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 77

10/28/2019

Company Report

Pages: 4

Prostate Cancer Foundation Scientific Retreat Takeaways; Solid Financial Position; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 78

09/23/2019

Company Report

Pages: 5

Leveraging the Digital Age; BXCL501 Program Initiative With Wearable Digital Devices; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 79

08/21/2019

Company Report

Pages: 4

Department of Defense Grant Award Underscores BXCL501 Value Proposition; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: BioXcel Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 80

08/07/2019

Company Report

Pages: 4

2Q19 Financial Results Reported; BXCL501 Pivotal Program Starting Soon; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party